Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Inclusion Criteria: * Written informed consent and any locally-required authorization obtained. * Histologically-confirmed diagnosis of stage III non-small cell lung cancer (NSCLC) * Age≥18 years * Life expectancy \>6 months * Body weight \>30kg * Subjects with non-small cell lung cancer deemed surgically resectable by an attending thoracic surgeon with lobectomy * ECOG Performance Status 0-1 * Normal bone marrow and organ function on routine laboratory tests, as defined in section 4.1 * Evidence of post-menopausal status or negative urinary/serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. * Ability to understand and willingness of sign consent form * Willingness to comply with the protocol for the duration of the study Exclusion Criteria: * Involvement in the planning and/or conduct of the study (includes AstraZeneca staff and staff at the study site) * Prior investigational therapy within 28 days/at least 5 half-lives before study drug administration * Prior chest radiation * Prior history of interstitial lung disease or pneumonitis requiring corticosteroids, or active non-infectious pneumonitis * Patients only suitable for surgical management with pneumonectomy, deemed by an attending thoracic surgeon * Prior therapy with PD-1, PD-L1, CTLA-4 or anti-cancer vaccines, including durvalumab and tremelimumab * Participation in another clinical st…